IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Nymox Pharmaceutical Corporation and Advises Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--

Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Nymox Pharmaceutical Corporation ("Nymox" or the "Company") NYMX concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The investigation concerns whether Nymox and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On August 10, 2016, an article was published in Seeking Alpha reporting that the Company's management misled shareholders about its prospects while aggressively dumping stock without timely SEC disclose. When this news was announced, shares of Nymox fell in value.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160810006259/en/